Paul v. Virginia (1868)

Paul v. Virginia was a landmark decision by the U.S. Supreme Court in 1868 that clarified the federal government's limited role in regulating insurance. This case established that insurance is not interstate commerce and, therefore, is not subject to federal regulation under the Commerce Clause of the U.S. Constitution.

Key features of Paul v. Virginia:

  • State Regulation: The decision upheld the traditional approach to insurance regulation, which delegated primary regulatory power to the individual states. This meant that states had the authority to regulate and oversee insurance companies operating within their borders.

  • Interstate Commerce: The Court ruled that insurance transactions are not part of interstate commerce, and therefore are not subject to federal regulation under the Commerce Clause of the U.S. Constitution. This decision established the foundation for the McCarran-Ferguson Act of 1945, which gave states the authority to regulate insurance.

  • Impact on Employee Benefits: The Paul v. Virginia decision has had a significant impact on the regulation of employee benefits, particularly in the areas of health and disability insurance. Because insurance is regulated at the state level, there is significant variation in the rules and regulations governing employee benefits across different states. This has made it challenging for employers to design and administer benefit plans that comply with all applicable state regulations.

Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.